Charter Trust Co. Has $9.84 Million Position in Eli Lilly And Co (LLY)

Charter Trust Co. lessened its holdings in Eli Lilly And Co (NYSE:LLY) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,719 shares of the company’s stock after selling 487 shares during the period. Eli Lilly And Co accounts for about 1.1% of Charter Trust Co.’s investment portfolio, making the stock its 28th biggest holding. Charter Trust Co.’s holdings in Eli Lilly And Co were worth $9,842,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Balasa Dinverno & Foltz LLC raised its holdings in Eli Lilly And Co by 15.9% in the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after acquiring an additional 499 shares during the period. FMR LLC increased its holdings in shares of Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after purchasing an additional 752,864 shares during the period. Blair William & Co. IL increased its holdings in shares of Eli Lilly And Co by 4.0% during the 3rd quarter. Blair William & Co. IL now owns 245,801 shares of the company’s stock worth $26,377,000 after purchasing an additional 9,532 shares during the period. Arizona State Retirement System increased its holdings in shares of Eli Lilly And Co by 0.8% during the 3rd quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock worth $29,893,000 after purchasing an additional 2,174 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Eli Lilly And Co by 26.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 906,840 shares of the company’s stock worth $97,186,000 after purchasing an additional 188,150 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Shares of Eli Lilly And Co stock opened at $115.84 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $119.84. The stock has a market cap of $123.43 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 1.82 and a beta of 0.31.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period in the previous year, the business earned $1.05 EPS. The firm’s revenue was up 7.1% on a year-over-year basis. Research analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 1.94%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.

In other news, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the sale, the senior vice president now directly owns 55,224 shares in the company, valued at approximately $5,870,863.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Eli & Co Lilly sold 4,500 shares of Eli Lilly And Co stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $14.44, for a total transaction of $64,980.00. Following the sale, the insider now owns 3,915,654 shares in the company, valued at $56,542,043.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,962,800 shares of company stock worth $149,601,553. 0.11% of the stock is owned by company insiders.

Several research analysts have recently issued reports on the stock. Citigroup downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price objective on the stock. in a report on Monday, November 26th. Credit Suisse Group upgraded shares of Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a report on Wednesday, October 31st. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. JPMorgan Chase & Co. set a $123.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Friday, October 5th. Finally, Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Thursday, September 27th. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $111.53.

COPYRIGHT VIOLATION NOTICE: “Charter Trust Co. Has $9.84 Million Position in Eli Lilly And Co (LLY)” was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.wkrb13.com/2018/12/07/charter-trust-co-has-9-84-million-position-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Are analyst ratings accurate?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply